Sangui Biotech International (Sangui Biotech International) Deferred Tax

: $0.00 Mil (TTM As of Mar. 2023)

View and export this data going back to . Start your Free Trial

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Sangui Biotech International's change in deferred tax for the three months ended in Mar. 2023 was $0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Mar. 2023 was $0.00 Mil.

Sangui Biotech International Deferred Tax Historical Data

The historical data trend for Sangui Biotech International's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangui Biotech International Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Deferred Tax

Sangui Biotech International Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Deferred Tax																-	-	-	-	-

Sangui Biotech International Deferred Tax Calculation

Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Sangui Biotech International Deferred Tax Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangui Biotech International (Sangui Biotech International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (OTCPK:SGBI) » Definitions » Deferred Tax

Comparable Companies

Traded in Other Exchanges

SBH:Germany

Address

Bleichenbrucke 9, Hamburg, DEU, 20354

Website

http://www.sanguibiotech.com

Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.

Executives

Hubertus Schmelz	director	NEUER WALL 54, HAMBURG 2M D-20354
Joachim Fleing	director	ALFRED HERRHAUSENSTR 44, WITTEN 2M 58455
Thomas Striepe	director	NEUER WALL 54, HAMBURG 2M D-20354
Wolfgang Barnikol	director	ALFRED HERRHAUSEN STR 44, WITTEN 2M 58455
Lutz Joachim	director	ALFRED-HERRHAUSEN-ST. 44, WITTEN 2M 58455
Christoph Ludz	director	SANDERSKOPPEL 17, HAMBURG 2M 22391

Sangui Biotech International (Sangui Biotech International) Headlines

No Headlines